B‐lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice
Open Access
- 30 April 2007
- journal article
- research article
- Published by Wiley in Immunology
- Vol. 122 (1), 73-79
- https://doi.org/10.1111/j.1365-2567.2007.02614.x
Abstract
Sjögren's syndrome is an autoimmune disease in which immune cells chronically attack the lachrymal and salivary glands. The Id3 knockout mouse is a newly established animal model for primary Sjögren's syndrome. To address the role of B cells in Sjögren's syndrome and autoimmune disease, we studied the effect of CD20 monoclonal antibody treatment on the disease in Id3 knockout mice. Antibody treatment at 2-month intervals led to efficient and sustained B-cell depletion in Id3 knockout mice. A significant improvement of histopathology was observed accompanied by the recovery of saliva secretory function after CD20 antibody treatment. We further show that serum immunoglobulin G3, which is abnormally high in untreated Id3 knockout mice, was reduced after CD20 antibody treatment. This study establishes a new animal model for immunotherapy of Sjögren's symptoms and suggests a possible link between immunoglobulin G3 and disease pathology in Id3 knockout mice.Keywords
This publication has 23 references indexed in Scilit:
- Clinical and immunological characteristics of patients with Sjogren's syndrome in relation to -fodrin antibodiesRheumatology, 2006
- Successful treatment of Sjogren's syndrome with rituximabScandinavian Journal of Rheumatology, 2006
- Update on rituximabAnnals Of The Rheumatic Diseases, 2005
- Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3213–228 in primary Sjögren's syndromeRheumatology, 2005
- A T Cell Intrinsic Role of Id3 in a Mouse Model for Primary Sjögren's SyndromeImmunity, 2004
- The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody ImmunotherapyThe Journal of Experimental Medicine, 2004
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- E2A proteins: essential regulators at multiple stages of B‐cell developmentImmunological Reviews, 2000
- Abnormal B lymphocyte delevopment, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction moleculeImmunity, 1995
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994